NASDAQ:AMRN Amarin (AMRN) Stock Price, News & Analysis $19.26 +0.42 (+2.20%) As of 01:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Amarin Stock (NASDAQ:AMRN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Amarin alerts:Sign Up Key Stats Today's Range$18.61▼$20.4250-Day Range$14.52▼$18.8452-Week Range$7.08▼$20.42Volume198,304 shsAverage Volume90,624 shsMarket Capitalization$398.19 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingSell Company Overview Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin’s primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies. The company’s flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events. Since its initial U.S. approval in 2012, Vascepa has received marketing authorizations in key markets including Canada, the European Union and Japan, often through strategic partnerships with regional pharmaceutical companies. Amarin manages its own commercial organization in the United States and leverages licensing agreements to support distribution and patient access abroad. In addition to its marketed portfolio, Amarin is conducting ongoing research to explore new indications for Vascepa and to expand its understanding of lipid-modifying therapies. Its clinical programs aim to investigate potential benefits in a range of cardiovascular and metabolic conditions. The company operates with a leadership team comprised of seasoned professionals in biopharmaceutical R&D, regulatory affairs and commercial strategy, supported by research facilities in the United States and Europe.AI Generated. May Contain Errors. Read More Amarin Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreAMRN MarketRank™: Amarin scored higher than 12% of companies evaluated by MarketBeat, and ranked 899th out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.1 / 5Analyst RatingSell Consensus RatingAmarin has received a consensus rating of Sell. The company's average rating score is 1.33, and is based on no buy ratings, 1 hold rating, and 2 sell ratings.Downside RiskAmarin has a consensus price target of $12.00, representing about 39.5% downside from its current price of $19.82.Amount of Analyst CoverageAmarin has only been the subject of 2 research reports in the past 90 days.Read more about Amarin's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Amarin are expected to decrease in the coming year, from ($0.15) to ($0.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amarin is -5.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amarin is -5.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmarin has a P/B Ratio of 0.84. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Amarin's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.96% of the float of Amarin has been sold short.Short Interest Ratio / Days to CoverAmarin has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Amarin has recently decreased by 4.59%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAmarin does not currently pay a dividend.Dividend GrowthAmarin does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.96% of the float of Amarin has been sold short.Short Interest Ratio / Days to CoverAmarin has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Amarin has recently decreased by 4.59%, indicating that investor sentiment is improving. News and Social Media2.6 / 5News Sentiment0.72 News SentimentAmarin has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Amarin this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for AMRN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Amarin insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.96% of the stock of Amarin is held by insiders.Percentage Held by InstitutionsOnly 22.25% of the stock of Amarin is held by institutions.Read more about Amarin's insider trading history. Receive AMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMRN Stock News HeadlinesHead-To-Head Review: Fortress Biotech (NASDAQ:FBIO) & Amarin (NASDAQ:AMRN)October 5 at 3:43 AM | americanbankingnews.comAmarin (NASDAQ:AMRN) Stock Passes Above 200 Day Moving Average - What's Next?September 30, 2025 | americanbankingnews.comThe next wave of AI fortunes may come from NVIDIA’s secret supplier.Bloomberg says AI is a $50 trillion revolution. And at the center of it… isn't NVIDIA. It's a tiny supplier NVIDIA cannot live without.October 6 at 2:00 AM | Behind the Markets (Ad)Amarin: Vascepa's Global Pivot From U.S. Squeeze To International BoomSeptember 29, 2025 | seekingalpha.comIonis upgraded at BMO Capital Markets after data for lipid-lowering agentSeptember 3, 2025 | msn.comAmarin stock rises after ESC Congress data on VASCEPA mechanismSeptember 2, 2025 | investing.comAmarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025August 31, 2025 | globenewswire.comNew REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces ...August 30, 2025 | finance.yahoo.comSee More Headlines AMRN Stock Analysis - Frequently Asked Questions How have AMRN shares performed this year? Amarin's stock was trading at $9.70 on January 1st, 2025. Since then, AMRN stock has increased by 104.3% and is now trading at $19.8190. How were Amarin's earnings last quarter? Amarin Corporation PLC (NASDAQ:AMRN) released its earnings results on Wednesday, July, 30th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.63. The biopharmaceutical company had revenue of $72.74 million for the quarter, compared to the consensus estimate of $45.45 million. Amarin had a negative trailing twelve-month return on equity of 21.18% and a negative net margin of 47.22%. Read the conference call transcript. When did Amarin's stock split? Amarin shares reverse split on the morning of Friday, April 11th 2025.The 1-20 reverse split was announced on Wednesday, March 12th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 10th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Does Amarin have any subsidiaries? The following companies are subsidiaries of Amarin: Ester Neurosciences, Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharmaceuticals Ireland Limited, Amarin Pharma Inc., Amarin Switzerland GmbH, Amarin UK Limited, and Ester Neurosciences Limited. How do I buy shares of Amarin? Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amarin own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amarin investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Last Earnings7/30/2025Today10/06/2025Next Earnings (Estimated)10/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AMRN CIK897448 Webwww.amarincorp.com Phone(531) 669-9020FaxN/AEmployees360Year Founded1991Price Target and Rating Average Price Target for Amarin$12.00 High Price Target$12.00 Low Price Target$12.00 Potential Upside/Downside-37.7%Consensus RatingSell Rating Score (0-4)1.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($3.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$82.18 million Net Margins-47.22% Pretax Margin-44.91% Return on Equity-21.18% Return on Assets-15.00% Debt Debt-to-Equity RatioN/A Current Ratio3.26 Quick Ratio2.34 Sales & Book Value Annual Sales$228.61 million Price / Sales1.74 Cash FlowN/A Price / Cash FlowN/A Book Value$23.62 per share Price / Book0.82Miscellaneous Outstanding Shares20,680,000Free Float20,278,000Market Cap$398.19 million OptionableOptionable Beta0.62 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:AMRN) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersWall Street legend: “Sell this A.I. stock now”Whats next after AI? Hidden AI. "Hidden AI" could soon be the biggest investment trend of 2025.Chaikin Analytics | SponsoredThe next wave of AI fortunes may come from NVIDIA’s secret supplier.Bloomberg says AI is a $50 trillion revolution. And at the center of it… isn't NVIDIA. It's a tiny suppl...Behind the Markets | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGOLD ALERTGold has shattered records, soaring past $3,800 an ounce... But Stansberry Senior Partner Dr. David "Doc" E...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Corporation PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.